This site is intended for healthcare professionals

BRII 196 + BRII 198 combination filed with FDA for emergency use authorization in COVID-19.- Brii Biosciences

Read time: 1 mins
Last updated:10th Oct 2021
Published:10th Oct 2021
Brii Biosciences announced the filing of an emergency use authorization (EUA) application for its investigational SARS-CoV-2 (virus that causes COVID-19) combination therapy, BRII 196 + BRII 198 with the FDA. Data to support the EUA filing will be submitted by the Company to the U.S. FDA on a rolling basis.
Condition: Coronavirus/COVID-19 Infection
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Related news and insights